Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.phrs.2020.104832 http://scihub22266oqcxt.onion/10.1016/j.phrs.2020.104832 32304747!7158830!32304747     free     free     free       Pharmacol+Res 2020 ; 156 (ä): 104832 Nephropedia Template TP {{tp|p=32304747|t=2020. Angiotensin receptor blockers and COVID-19 |pdf=|usr=}}{{32304747}} gab.com Text Angiotensin receptor blockers and COVID-19 JO: Pharmacol Res http://www.kidney.de/pget.php?&tw=1&pmid=32304747 #FOAvip Angiotensin Receptor Blockers (ARBs) exhibit major pleiotropic protecting effects beyond their antihypertensive properties, including reduction of inflammation. ARBs directly protect the lung from the severe acute respiratory syndrome as a result of viral infections, including those from coronavirus. The protective effect of ACE2 is enhanced by ARB administration. For these reasons ARB therapy must be continued for patients affected by hypertension, diabetes and renal disease, comorbidities of the current COVID-19 pandemic. Controlled clinical studies should be conducted to determine whether ARBs may be included as additional therapy for COVID-19 patients. Twit Text FOAVip Angiotensin receptor blockers and COVID-19 ????Pharmacol Res http://www.kidney.de/pget.php?&tw=1&pmid=32304747 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32304747 #FOAvip English Wikipedia <ref>{{Cite pmid|32304747}}</ref> Angiotensin receptor blockers and COVID-19 #MMPMID32304747 Saavedra JM Pharmacol Res 2020[Jun]; 156 (ä): 104832 PMID32304747show ga Angiotensin Receptor Blockers (ARBs) exhibit major pleiotropic protecting effects beyond their antihypertensive properties, including reduction of inflammation. ARBs directly protect the lung from the severe acute respiratory syndrome as a result of viral infections, including those from coronavirus. The protective effect of ACE2 is enhanced by ARB administration. For these reasons ARB therapy must be continued for patients affected by hypertension, diabetes and renal disease, comorbidities of the current COVID-19 pandemic. Controlled clinical studies should be conducted to determine whether ARBs may be included as additional therapy for COVID-19 patients. |*Diabetes Mellitus[MESH] |*Hypertension[MESH] |Angiotensin Receptor Antagonists[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |Coronavirus Infections[MESH] |Humans[MESH] |Pandemics[MESH] |Peptidyl-Dipeptidase A[MESH] |Pneumonia, Viral[MESH]Angiotensin receptor blockers and COVID-19 (epmc).pdf DeepDyve Pubget Overpricing